Skip to content
Screener

Zymeworks ZYME Exchangeable shares, shares outstanding (in shares)

Exchangeable shares, shares outstanding (in shares) at other companies

Blue Bird Corporation logo
Blue Bird CorporationBLBD
2.7M
Blue Bird Corporation logo
Blue Bird CorporationBLBD
$2.7M
COA
Hemab Therapeutics Holdings, Inc.COAG
$0
COA
Hemab Therapeutics Holdings, Inc.COAG
0
Welltower logo
WelltowerWELL
8.5M+93.8%
Blue Bird Corporation logo
Blue Bird CorporationBLBD
2.7M

Other financials

Income statement

See full
Revenue$4.6M-90.6%
Operating income-$42.2M-6,158%
Net income-$45.0M-2,043%
EPS (diluted)-$0.62-2,167%

Balance sheet

See full
Cash & equivalents$179.4M+82.6%
Total debt$16.0M-14.3%
Total equity$80.4M-76.0%
Total assets$397.0M-2.8%

Cash flow

See full
Operating cash flow-$31.9M-365%
CapEx$216.0K+1,250%
Free cash flow-$31.9M-376%

Valuation

See full
Market cap$1.71B+82.0%
Enterprise value$1.55B+79.8%
P/S46.2×+38.5×

Profitability

See full
Operating margin-419%-518pp
Net margin-404%-489pp
FCF margin-324.7%-366pp

Returns & leverage

See full
Return on equity-72.3%-117pp
Debt / equity0.2×+0.1×
Current ratio6.3×-1.4×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept zyme:ExchangeableSharesOutstanding.

The source filing: Zymeworks’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001937653-26-000047
AssetsJune 30,2026 / (unaudited)December 31,2025
Stockholders’ equity:
Common stock, $0.00001 par value; 900,000,000 authorized shares at June 30, 2026 and December 31, 2025, respectively; 71,412,072 and 74,638,413 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively1,133,9591,105,176
Preferred shares, $0.00001 par value; 100,000,000 authorized shares of preferred stock, out of which, one share of preferred stock is a share of Special Voting Preferred Stock and outstanding as of June 30, 2026 and December 31, 2025
Exchangeable shares, no par value, 550,000 and 553,184 issued and outstanding shares at June 30, 2026 and December 31, 2025, respectively7,8927,938
Additional paid-in capital116,450114,626
Accumulated other comprehensive loss(6,694)(6,079)
Accumulated deficit(1,171,238)(953,160)
Total stockholders’ equity80,369268,501

Item 1. Financial Statements

FAQ

What is Zymeworks's exchangeable shares, shares outstanding (in shares)?
Zymeworks (ZYME) reported exchangeable shares, shares outstanding (in shares) of $550K in Q2 2026.
How has Zymeworks's exchangeable shares, shares outstanding (in shares) changed year-over-year?
Zymeworks's exchangeable shares, shares outstanding (in shares) decreased by 3.5% year-over-year, from $569.9K to $550K.
What is the long-term trend for Zymeworks's exchangeable shares, shares outstanding (in shares)?
Over 3 years (2022 to 2025), Zymeworks's exchangeable shares, shares outstanding (in shares) has grown at a -27.0% compound annual growth rate (CAGR), from $1.42M to $553.18K.
What does exchangeable shares, shares outstanding (in shares) mean?
Exchangeable shares, shares outstanding (in shares) as reported by Zymeworks Inc..

Ask your AI about Zymeworks's exchangeable shares, shares outstanding (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude